We have used homologous recombination to disrupt the mouse gene coding for
the NaK2Cl cotransporter (NKCC2) expressed in kidney epithelial cells of th
e thick ascending limb and macula densa. This gene is one of several that w
hen mutated causes Bartter's syndrome in humans, a syndrome characterized b
y severe polyuria and electrolyte imbalance. Homozygous NKCC2-/- pups were
born in expected numbers and appeared normal. However, by day 1 they showed
signs of extracellular volume depletion (hematocrit 51%; wild type 37%). T
hey subsequently failed to thrive. By day 7, they were small and markedly d
ehydrated and exhibited renal insufficiency, high plasma potassium, metabol
ic acidosis, hydronephrosis of varying severity, and high plasma renin conc
entrations. None survived to weaning. Treatment of -/- pups with indomethac
in from day 1 prevented growth retardation and 10% treated for 3 weeks surv
ived, although as adults they exhibited severe polyuria (10 ml/day), extrem
e hydronephrosis, low plasma potassium, high broad pH, hypercalciuria, and
proteinuria. Wild-type mice treated with furosemide, an inhibitor of NaK2Cl
cotransporters, have a phenotype similar to the indomethacin-rescued -/- a
dults except that hydronephrosis was mild. The polyuria, hypercalciuria, an
d proteinuria of the -/- adults and furosemide-treated wild-type mice were
unresponsive to inhibitors of the renin angiotensin system, vasopressin, an
d further indomethacin. Thus absence of NKCC2 in the mouse causes polyuria
that is not compensated elsewhere in the nephron. The NKCC2 mutant animals
should be valuable for uncovering new pathophysiologic and therapeutic aspe
cts of genetic disturbances in water and electrolyte recovery by the kidney
.